MedPath

Efficacy and Safety of Activated Recombinant Human Factor VII in Treatment of Bleeding in Patients Following Hematopoietic Stem Cell Transplantation

Phase 2
Terminated
Conditions
Bleeding During/Following Surgery
Acquired Bleeding Disorder
Interventions
Drug: standard therapy
Drug: activated recombinant human factor VII
Drug: placebo
Registration Number
NCT01564563
Lead Sponsor
Novo Nordisk A/S
Brief Summary

This trial is conducted in the United States of America (USA). The aim of this trial is to evaluate the efficacy of activated recombinant human factor VII in treatment of bleeding in patients having undergone a hematopoietic stem cell transplantation.

Detailed Description

Not available

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
11
Inclusion Criteria
  • Patients who have undergone a hematopoietic stem cell transplantation
Read More
Exclusion Criteria
  • Known or suspected allergy to trial product
  • Participation in other trials with unapproved drugs or trials with equal or similar objective
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Placebostandard therapy-
High dosestandard therapy-
Low doseactivated recombinant human factor VII-
Placeboplacebo-
High doseactivated recombinant human factor VII-
Low dosestandard therapy-
Primary Outcome Measures
NameTimeMethod
Effect on bleeding, defined as change in bleeding score
Secondary Outcome Measures
NameTimeMethod
Changes in safety coagulation parameters
Transfusion requirements
Bleeding evaluation
Adverse events

Trial Locations

Locations (1)

Novo Nordisk Investigational Site

🇺🇸

Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath